Cambridge, MA - CluePoints, a leading provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, today announced their collaboration with Oracle Health Sciences, combining CluePoints' award-winning risk-based monitoring (RBM) solution with Oracle’s clinical data capture and management platform, Oracle Health Sciences Inform Cloud Service. The resulting solution can help deliver a complete trial review process that proactively identifies risk in both clinical and operational data throughout a clinical trial. These include operational risks, such as those outlined by industry consortiums, as well as risks seen through the analysis of clinical data that highlight anomalies or inconsistent data patterns at study, region or site levels that otherwise may not have been identified.
This collaboration brings together CluePoints' Central Statistical Monitoring (CSM) solution, which identifies anomalous data and site errors, with clinical and operational data from Oracle Health Sciences to analyze and identify risks, and ultimately optimize both remote and on-site monitoring. By offering sponsors and CROs full evaluation and proactive identification of risks identified through both clinical and operational data, customers are able to respond to signals and anomalies that could impact patient safety and the quality of results, while also driving informed decision-making for future stages of a trial and minimizing subsequent regulatory submission risk.
The combination of CluePoints' solution and Oracle's holistic RBM cloud platform can allow identification of risks based on patient data, site level or region using clinical data from the InForm platform, and, as a result, complementing existing RBM capabilities that identify operational risks for a study. The detection of risks identified through both operational and clinical data provides customers with the ability to fully respond to data issues and make changes to study protocols to effectively address and minimize study risk.
"We are thrilled to be working with Oracle Health Sciences on the integration of our technologies," says FranÒ«ois Torche, CEO, CluePoints. "It is well understood how vital accurate data is to a clinical trial. By bringing together a combined technology solution, customers can now proactively resolve risks and ensure that they have detailed insight into data at all stages of a clinical trial."
CluePoints and Oracle Health Sciences have announced an upcoming webinar, entitled 'De-risking It All - A Systematic and Proven Approach to RBM and Data Quality Oversight", providing the opportunity to learn from industry experts how a unique combination of data analytics and Electronic Data Capture is being harnessed by large, medium and smaller Pharma to de-risk clinical studies and drive Risk-Based Monitoring. To register, please visit this website today.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
Phase II ALPACA Trial Shows Lepodisiran Produces Significant, Sustained Lipoprotein(a) Reductions
March 31st 2025Eli Lilly’s lepodisiran, an investigational siRNA therapy, achieved significant and durable reductions in lipoprotein(a) levels, a major genetic risk factor for cardiovascular disease.